DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azilect (Rasagiline Mesylate) - Summary



AZILECT® tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinson's disease.

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

The effectiveness of AZILECT was demonstrated in patients with early Parkinson's disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy. The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson's disease who were treated with levodopa.

See all Azilect indications & dosage >>


Media Articles Related to Azilect (Rasagiline)

Researchers identify visual system changes that may signal Parkinson's disease
Source: Eye Health / Blindness News From Medical News Today [2017.07.14]
Changes in the visual systems of newly diagnosed Parkinson's disease patients may provide important biomarkers for the early detection and monitoring of the disease, according to a new study...

Parkinson's Disease and Melanoma May Occur Together, Study Finds
Source: MedicineNet Melanoma Specialty [2017.07.10]
Title: Parkinson's Disease and Melanoma May Occur Together, Study Finds
Category: Health News
Created: 7/7/2017 12:00:00 AM
Last Editorial Review: 7/10/2017 12:00:00 AM

Transcranial stimulation and/or physical therapy improves walking speed in Parkinson's disease
Source: Rehabilitation / Physical Therapy News From Medical News Today [2017.06.29]
Noninvasive brain stimulation and physical therapy - alone or in combination - improve some measures of walking ability in patients with Parkinson's disease (PD), concludes a clinical trial in the...

Statins may raise the risk of Parkinson's disease
Source: Statins News From Medical News Today [2017.06.15]
New research suggests that rather than protecting against Parkinson's disease, it is possible that the use of statins may increase its risk.

Research provides new insights into the cause of urinary dysfunction in Parkinson's disease
Source: Urology / Nephrology News From Medical News Today [2017.06.12]
A new study from the University of Hertfordshire, published in the journal PLOS ONE, has found that urinary dysfunction and incontinence observed among Parkinson's disease sufferers may start at the...

more news >>

Published Studies Related to Azilect (Rasagiline)

Rasagiline treatment effects on parkinsonian tremor. [2013]
Tremor is a common symptom of Parkinson's disease (PD). The underlying pathophysiology of parkinsonian rest tremor is not well understood... These data suggest that rasagiline used as monotherapy and as adjunctive therapy is effective for reducing tremor severity in patients with PD.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study... INTERPRETATION: These findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasagiline 1 mg per day early-start versus delayed-start group. The rate of UPDRS deterioration was less than was anticipated from previous studies and correlated with baseline severity. Understanding of the pattern of UPDRS deterioration is essential to assess disease modification. FUNDING: Teva Pharmaceutical Industries and H Lundbeck A/S. Copyright (c) 2011 Elsevier Ltd. All rights reserved.

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...

Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension... Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive.The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.

more studies >>

Clinical Trials Related to Azilect (Rasagiline)

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline [Completed]

Azilect´┐Ż (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China [Completed]
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese patients with motor fluctuations. Azilect« (Rasagiline) is indicated for the treatment of idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease [Completed]

Azilect + Antidepressant Chart Review [Completed]
To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:

- Group 1 Patients using Azilect and no other therapy.

- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or


more trials >>

Reports of Suspected Azilect (Rasagiline) Side Effects

Dizziness (15)Drug Interaction (14)Headache (13)Arthralgia (11)Dyskinesia (9)Fall (9)Hallucination (9)Diarrhoea (9)Insomnia (9)Confusional State (8)more >>

Page last updated: 2017-07-14

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017